NIH-funded research NIH-funded research

Optimizing long-acting PrEP and opioid treatment for people in jails and prisons

Official title: NOTRE: optimizing long-acting pre-exposure prophylaxis and medications for opioid use disorder interventions in carceral settings

Funded at Duke University · NIH-11565766 · Data updated 2026-11-12

This project tests a real-world approach to using long-acting PrEP and buprenorphine for HIV prevention and opioid treatment among incarcerated individuals and after release.

More Opioid Use research and trials

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionDuke University
NIH-funded
Lab location1 site (Durham, United States)
Project startMay 15, 2024
Project endJuly 31, 2029
Funding year2026
Award (this year)$149,764
NIH project number3R33DA060583-03S1
Project IDNIH-11565766 on NIH RePORTER

Who could benefit from this research

Could help

Adults with opioid use disorder and/or HIV risk factors who are incarcerated and eligible for PrEP and MOUD in selected correctional settings or during reentry.

Less likely to help

Individuals without OUD or HIV risk, or those not in correctional settings or post-release care pathways, may see no direct benefit.

What this research studies

People in correctional settings face high HIV risk and opioid use disorders. The study will create and test a delivery protocol for long-acting injectable PrEP plus long-acting buprenorphine, and compare it with the standard oral PrEP and sublingual buprenorphine. It uses a hybrid implementation-effectiveness design to see how well the approach works in prison and after release in Maryland and Washington, DC. The goal is to find scalable practices that keep people engaged in treatment and reduce HIV risk and opioid-related harms. Researchers will measure how easily clinics can implement the approach and whether outcomes improve compared with current care.

Why it matters

Potential benefit: If successful, this could lead to more consistent HIV prevention and opioid treatment for incarcerated individuals, reducing HIV transmission and improving health after release.

How similar studies have gone: Prior work suggests that long-acting PrEP and MOUD can improve adherence; this study tests a combined, packaged approach in a high-need setting.

Where this research is happening

  • Duke University
    Durham, United States
    Active

Researchers

  • Principal investigator: Brinkley-Rubinstein, Lauren — Duke University
  • Study coordinator: Brinkley-Rubinstein, Lauren

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.